Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Day One Biopharmaceuticals Inc. is active in the Biotechnology & Pharmaceuticals technology area, where it currently has 1 pending office action. This activity is situated within 1 distinct art unit. This suggests a very specific technical focus for the company's current patenting activity. This concentration indicates a strategic emphasis on a particular technical niche within the Biotechnology & Pharmaceuticals sector.
The prosecution involves 1 distinct examiner. JANOSKO, CHASITY PAIGE is the busiest examiner for the portfolio, handling 1 pending office action. This indicates that the company's current patent office workload is not distributed among multiple examiners. The use of 1 distinct examiner suggests a centralized review process where all communication is directed through this official, which simplifies the management of the portfolio.
The profile shows a concentrated prosecution effort with 1 pending office action and 1 distinct examiner. For practitioners, the involvement of 1 distinct art unit means that the company's current intellectual property strategy is focused on a single technical domain. Since JANOSKO, CHASITY PAIGE handles 1 pending office action, the outcome depends on this individual's interpretation of the claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JANOSKO, CHASITY PAIGE | 1 | 15.9% | +63.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17824237 | SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR | JANOSKO, CHASITY PAIGE | 74d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17824237 | SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR | JANOSKO, CHASITY PAIGE | 74d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17824237 | SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR | JANOSKO, CHASITY PAIGE | 1613 | §103 | Final Rejection | 74d overdue | Pending | May 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial